At Radisens Diagnostics, we're building the next generation of portable diagnostic platforms and consummable suites. Find out about this high growth decentralised diagnostics marketplace, or learn more about our disruptive technology.
For Investors
No portable diagnostic device on the market delivers such a wide range of cell-, immuno- and molecular-based diagnostic and screening assays at point-of-care on a single platform, with all sample preparation steps integrated into one simple consummable format. The medical diagnostics industry is scrambling to serve this healthcare-driven need for decentralised diagnostics, a market worth US$36bn, growing at 15% annually. Radisens' significant early market traction is testament to experienced management team, disruptive patent-pending technology, strong IP portfolio and unique value proposition.
The Technology
Radisens is leading a step-change towards portable instruments for medical professionals in GP clinics, physician-office labs, outpatient and emergency departments, and other point-of-care settings. Radisens offers one robust platform offering multiple clinical tests using a finger-prick of blood or urine, with results within 10 minutes. Based on gold-standard optical flow cytometry, Radisens' digital technology delivers multi-coloured fluorescent and scattering detection over seven decades of dynamic range, with all sample preparations steps integrated into one simple consummable format.
Latest News
- French Angel Fund invests in Radisens
- Point-of-Care testing market set to reach $25Bn by 2013
- Radisens licenses nanophotonics technology from Stanford
- Radisens announces European funding award for cancer screening
- Radisens appoints Kevin Fielding and Gary Kennedy to Board
- Radisens wins “most investable startup” award from European business angel networks